Zentalis Pharmaceuticals (ZNTL) Return on Capital Employed (2022 - 2025)
Historic Return on Capital Employed for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to 0.55%.
- Zentalis Pharmaceuticals' Return on Capital Employed fell 400.0% to 0.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55%, marking a year-over-year decrease of 400.0%. This contributed to the annual value of 0.44% for FY2024, which is 1900.0% up from last year.
- Latest data reveals that Zentalis Pharmaceuticals reported Return on Capital Employed of 0.55% as of Q3 2025, which was down 400.0% from 0.56% recorded in Q2 2025.
- Zentalis Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.48% during Q4 2022, with a 5-year trough of 0.6% in Q4 2023.
- Its 4-year average for Return on Capital Employed is 0.53%, with a median of 0.52% in 2024.
- Per our database at Business Quant, Zentalis Pharmaceuticals' Return on Capital Employed plummeted by -1200bps in 2023 and then soared by 1100bps in 2024.
- Zentalis Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.48% in 2022, then decreased by -26bps to 0.6% in 2023, then increased by 18bps to 0.49% in 2024, then fell by -11bps to 0.55% in 2025.
- Its last three reported values are 0.55% in Q3 2025, 0.56% for Q2 2025, and 0.59% during Q1 2025.